** Shares of vaccine maker Moderna fall 13.6% to $36.20 premarket
** Co cut its 2025 sales forecast by $1 billion, hurt by a slow launch of its respiratory syncytial virus (RSV) shot and weak demand for COVID-19 vaccines
** Co expects $1.5 bln to $2.5 bln in annual revenue, lower than its prior forecast of $2.5 bln to $3.5 bln
** Analysts on average were expecting annual revenue of $2.95 bln, according to data from LSEG
** Co expects to end 2025 with cash and investments of about $6 billion
** Up to last close, stock had fallen 61.4% in the past 12 months
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。